Is Chewy Inc a Buy After Its Latest Earnings Report?

Chewy shares fell another 5% after fiscal Q1 results and cautious full-year guidance, leaving the stock down 43% year to date and 84% below its pandemic peak. Q1 net sales rose 7.7% to $3.36 billion and EPS increased to $0.43, but management said customer additions will land toward the low end of the 150,000-250,000 forecast and full-year sales are now seen at $13.4 billion-$13.55 billion. Analysts turned more cautious, with target cuts from Morgan Stanley, Bank of America, and Piper Sandler, while MoffettNathanson downgraded the stock to Neutral.

Analysis

The market is treating CHWY less like a compounding consumer platform and more like a cyclical retailer with a fragile customer-acquisition engine. The key second-order effect is that slower net adds compress the lifetime-value math faster than current margin improvements can offset, because fulfillment, marketing, and veterinary expansion costs were likely being justified on a larger future active base. That creates a valuation trap: the multiple can look optically cheap on forward earnings while the denominator for those earnings is getting less reliable.

Competitive dynamics are also more nuanced than the headline suggests. WOOF’s relative stability implies the category isn’t breaking, but it does hint that omnichannel and store-based convenience may be outperforming pure e-commerce when household budgets tighten. If CHWY is forced to defend share with promotions or shipping incentives, the margin gains from AI-driven savings could be recycled back into customer retention, limiting operating leverage over the next 2-3 quarters.

The near-term catalyst path is asymmetric to the downside: analyst cuts can continue until the market sees evidence of re-accelerating customer adds, not just revenue growth from higher ticket sizes. A meaningful reversal likely needs either a consumer relief tailwind over the next several months or proof that vet-clinic monetization is driving higher-frequency, stickier behavior. Absent that, the stock may trade on each guidance reset rather than on reported beats.

Contrarian angle: consensus may be underestimating how quickly pet spend can normalize once households feel budget pressure, especially for discretionary treats, supplements, and convenience services. But the more important contrarian setup is not a fundamental collapse — it is that the stock can remain cheap for longer because estimate revisions are still catching up to slower cohort growth. That makes this more suitable for tactically bearish positioning than for conviction long exposure right now.

Key Decisions for Investors

• Stay short CHWY into any post-downgrade bounce over the next 2-6 weeks; risk/reward favors fading relief rallies until customer acquisition inflects, with downside likely driven by further estimate cuts rather than earnings misses.
• Pair trade: long WOOF / short CHWY for the next 1-3 quarters; if category demand is intact but channel mix is shifting toward omnichannel convenience, WOOF should outperform on relative traffic resilience while CHWY remains exposed to weaker net adds.
• Avoid initiating fresh long CHWY until the next two reporting periods confirm customer-add acceleration; current setup offers limited upside because margin expansion may be offset by higher retention and acquisition spend.
• For aggressive traders, buy CHWY put spreads expiring 2-4 months out to express a controlled downside view ahead of the next guidance reset; this monetizes revision risk while capping premium outlay.
• Watch for a tactical long only if CHWY guides back above the low end of customer additions and shows stable repeat-order metrics; that would signal the multiple deserves expansion, otherwise the stock remains a value trap.